Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
80 | Publisher: Grand View Research
Industry: Medical Devices | Report Format: Electronic (PDF)
The global neurodiagnostics market was valued at 13.6 billion in 2015 and is expected to reach a value of USD 18.3 billion by 2024, according to a new report by Grand View Research, Inc. Key factors driving the market growth include increasing prevalence of neurological diseases due to demographic changes and growing awareness of their management. In addition, consistent technological modifications coupled with increased preference for novel diagnostic technologies will further fuel the market. The economic burden of neurological diseases is extremely high on society and governments with around 1 billion people suffering globally. Among all the neuroimaging techniques, computed tomography has the largest market share followed by Magnetic Resonance Imaging (MRI). Computed Tomography (CT) uses ionized radiations for the purpose of creating images, whereas MRI uses radio waves in a magnetic field. Neuroimaging techniques are used to detect brain injuries, developmental malformations in the brain area, vascular irregularities that may lead to stroke, epilepsy, etc. Biomarkers are an important part of in vitro diagnostics for neurological disorders as their development is targeted at the early disease diagnosis with information about nervous system. Although biomarkers are not commercially available in the market, their use is confined to clinical research settings. For instance, ELISA tests for Tau protein are available in clinical studies of Alzheimer's disease. In addition, neuroinformatics is a field that studies neuroscience and information technology. This integration allows the storage of neurological data in the form databases. The neuroinformatics market is expected to grow at second highest growth rate during the forecast period. Further Key Findings From the Study Suggest: Increased life expectancy has resulted in increased geriatric population across the globe. The prevalence of aging-related neurological diseases such as Alzheimer's disease and Parkinson's disease is on the rise. The diagnosis of these diseases includes neuroimaging, in vitro diagnosis, and neuroinformatics. CT and MRI are the most commonly used imaging techniques across the globe, which are mainly used to detect brain abnormalities. Neurological biomarkers are extremely promising as they provide a direction to the diagnostic studies. Although currently no commercial biomarker is available in the market, an extensive clinical research is happening to find out the perfect combinations of the biomarkers. North America held the major market share of around 36% in the year 2015 and will retain its top position during the forecast period. On the other hand, Asia Pacific will exhibit highest CAGR of 4% over the forecast period.
Table of Contents
Chapter 1 Methodology & Scope
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 Market Summary
Chapter 4 Market Variables, Trends& Scope
4.1 Market Segmentation & Scope
4.1.1 Market driver analysis
4.1.2 Market restraint analysis
4.2 Penetration & Growth Prospect Mapping
4.3 Neurodiagnostics Market - SWOT Analysis, by Factor (Political & Legal,
Economic and Technological)
4.4 Industry Analysis - Porter's
Chapter 5 Market Categorization 1: Technology Estimates & Trend Analysis
5.1 Neurodiagnostics Market: Technology Movement Analysis
5.2 Neuroimaging Technologies
5.2.1 Computed tomography (CT)
5.2.2.1 CT market, 2013 - 2024 (USD Million)
5.2.2 Magnetic resonance imaging (MRI)
5.2.2.2 MRI market, 2013 - 2024 (USD Million)
5.2.3 Nuclear medicine imaging (PET, SPECT)
5.2.3.1 Nuclear medicine imaging (PET, SPECT) market, 2013 - 2024 (USD Million)
5.2.4 Near infrared spectroscopic imaging (NIRS)
5.2.4.1 NIRS market, 2013 - 2024 (USD Million)
5.2.5 Electroencephalography (EEG)
5.2.5.1 EEG market, 2013 - 2024 (USD Million)
5.2.6 Magnetoencephalography (MEG)
5.2.6.1 MEG market, 2013 - 2024 (USD Million)
5.2.7 Voxel-based Morphometry (VBM)
5.2.7.1 VBM (VBM) market, 2013 - 2024 (USD Million)
5.3 In Vitro Diagnostics
5.3.1 In vitro diagnostics market, 2013 - 2024 (USD Million)
5.4 Neuroinformatics
5.4.1 Neuroinformatics market, 2013 - 2024 (USD Million)
Chapter 6 Market Categorization 2: Regional Estimates & Trend Analysis, by Technology
6.1 Neurodiagnostics Market Share by Region, 2013 & 2024
6.2 North America
6.2.1 U.S.
6.2.2 Canada
6.3 Europe
6.3.1 UK
6.3.2 Germany
6.4 Asia Pacific
6.4.1 Japan
6.4.2 China
6.4.3 India
6.5 Latin America
6.5.1 Mexico
6.5.2 Brazil
6.6 MEA
6.6.1 South Africa
Chapter 7 Competitive Landscape
7.1 Strategy Framework
7.2 Company Profiles
7.2.1 Agilent Technologies
7.2.1.1 Company overview
7.2.1.2 Financial performance
7.2.1.3 Product benchmarking
7.2.1.4 Strategic initiatives
7.2.2 Alpha Omega Ltd.
7.2.2.1 Company overview
7.2.2.2 Financial performance
7.2.2.3 Product benchmarking
7.2.2.4 Strategic initiatives
7.2.3 Bruker
7.2.3.1 Company overview
7.2.3.2 Financial performance
7.2.3.3 Product benchmarking
7.2.3.4 Strategic initiatives
7.2.4 Doric Lenses, Inc.
7.2.4.1 Company overview
7.2.4.2 Financial performance
7.2.4.3 Product benchmarking
7.2.4.4 Strategic initiatives
7.2.5 Fonar Corporation
7.2.5.1 Company overview
7.2.5.2 Financial performance
7.2.5.3 Product benchmarking
7.2.5.4 Strategic initiatives
7.2.6 GE Healthcare
7.2.6.1 Company overview
7.2.6.2 Financial performance
7.2.6.3 Product benchmarking
7.2.6.4 Strategic initiatives
7.2.7 Guerbet
7.2.7.1 Company overview
7.2.7.2 Financial performance
7.2.7.3 Product benchmarking
7.2.7.4 Strategic initiatives
7.2.8 Hitachi Medical Corporation
7.2.8.1 Company overview
7.2.8.2 Financial performance
7.2.8.3 Product benchmarking
7.2.8.4 Strategic initiatives
7.2.9 Hologic, Inc.
7.2.9.1 Company overview
7.2.9.2 Financial performance
7.2.9.3 Product benchmarking
7.2.9.4 Strategic initiatives
7.2.10 Mightex Systems
7.2.10.1 Company overview
7.2.10.2 Financial performance
7.2.10.3 Product benchmarking
7.2.10.4 Strategic initiatives
7.2.11 NeuroNexus Technologies
7.2.11.1 Company overview
7.2.11.2 Financial performance
7.2.11.3 Product benchmarking
7.2.11.4 Strategic initiatives
7.2.12 Neusoft Medical Systems Co., Ltd.
7.2.12.1 Company overview
7.2.12.2 Financial performance
7.2.12.3 Product benchmarking
7.2.12.4 Strategic initiatives
7.2.13 Philips Healthcare
7.2.13.1 Company overview
7.2.13.2 Financial performance
7.2.13.3 Product benchmarking
7.2.13.4 Strategic initiatives
7.2.14 Plexon, Inc.
7.2.14.1 Company overview
7.2.14.2 Financial performance
7.2.14.3 Product benchmarking
7.2.14.4 Strategic initiatives
7.2.15 Plexon, Inc.
7.2.15.1 Company overview
7.2.15.2 Financial performance
7.2.15.3 Product benchmarking
7.2.15.4 Strategic initiatives
7.2.16 Roche Diagnostics
7.2.16.1 Company overview
7.2.16.2 Financial performance
7.2.16.3 Product benchmarking
7.2.16.4 Strategic initiatives
7.2.17 Siemens Healthcare
7.2.17.1 Company overview
7.2.17.2 Financial performance
7.2.17.3 Product benchmarking
7.2.17.4 Strategic initiatives
7.2.18 Toshiba Medical Systems Corporation
7.2.18.1 Company overview
7.2.18.2 Financial performance
7.2.18.3 Product benchmarking
7.2.18.4 Strategic initiatives
List of Tables TABLE 1 Country share estimation TABLE 2 North America neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 3 North America neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 4 U.S. Neurodiagnostics market, by Technology, 2013 - 2024 (USD Million) TABLE 5 U.S. neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 6 Canada neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 7 Canada neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 8 Europe neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 9 Europe neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 10 U.K. neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 11 U.K. neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 12 Germany neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 13 Germany neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 14 Asia Pacific neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 15 Asia Pacific neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 16 Japan neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 17 Japan neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 18 China neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 19 China neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 20 India neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 21 India neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 22 Latin America neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 23 Latin America neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 24 Mexico neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 25 Mexico neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 26 Brazil neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 27 Brazil neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 28 MEA neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 29 MEA neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million) TABLE 30 South Africa neurodiagnostics market, by technology, 2013 - 2024 (USD Million) TABLE 31 South Africa neurodiagnostics market, by neuroimaging technology, 2013 - 2024 (USD Million)
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
